Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab with Abiraterone Acetate and Prednisone in Metastatic Castration-resistant Prostate Cancer
NCT01688492Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2012
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in castration-resistant prostate cancer (CRPC), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2012; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01688492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01688492.